Acute Myelogenous Leukemia (AML)

Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a bone marrow cancer in which hematopoietic progenitors are stopped in their maturation at an early stage. The development of more than 20 percent blasts in the bone marrow distinguishes most acute myelogenous leukemia subtypes from other similar blood diseases.

Acute myelogenous leukemia (AML) is the most frequent kind of acute leukemia in adults, accounting for about 80 percent of cases. The incidence of acute myelogenous leukemia in the United States is from 3 to 5 cases per 100,000 people. In only one year, an estimated 20,800 new cases were diagnosed, with over 10,500 people dying as a result of cancer. Acute myelogenous leukemia prevalence rises with age, from 1.5 cases per 100 000 people in patients under 65 to 12.5 cases per 100 000 people in those above 65. Despite the fact that developments in acute myelogenous leukemia treatment have resulted in significant improvements in survival rates, the prognosis is still very bad in the elderly population.

Patients with Acute myelogenous leukemia may experience health problems as a result of bone marrow suppression, organ invasion with leukemic cells, or both. The duration of the event is varied. Blood testing, bone marrow aspiration and biopsy (the definitive diagnostic tests), and genetic abnormalities analysis are all part of the acute myelogenous leukemia workup.

Only a small percentage of acute myelogenous leukemia patients are cured by current standard treatment protocols. As a result, all patients should be assessed for eligibility to participate in well-designed clinical studies. In the absence of a clinical trial, the patient can be treated with conventional therapy. The treatment of adverse consequences of chemotherapy frequently necessitates hospitalization.